Madrigal names Mardi Dier as CFO; Alex Howarth transitions to advisor; GC Brian Lynch to depart by May 31

MADRIGAL PHARMACEUTICALS, INC.

Mardi Dier appointed SVP & CFO effective March 11, 2024; previously CFO of Acelyrin (IPO), Ultragenyx, Portola.
Dier receives $550K base salary, 45% target bonus, and $6.7M equity grant (RSUs, options, PSUs) under 2023 Inducement Plan.
Outgoing CFO Alex Howarth remains Senior Advisor to May 31; separation includes 12-month salary, target bonus, equity acceleration, health benefits.
SVP & General Counsel Brian Lynch to depart by May 31; similar separation terms: 12-month salary, target bonus, equity acceleration, health benefits.
No disagreements with accounting policies or internal controls related to either departure.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Mardi C. Dier

Senior Vice President and Chief Financial Officer

MDGL · MADRIGAL PHARMACEUTICALS, INC.

Effective: 2024-03-11
Filed: February 28, 2024, 6:59 PM ET

On February 28, 2024, Madrigal Pharmaceuticals, Inc. (the “Company”) announced the appointment of Mardi C. Dier as Senior Vice President and Chief Financial Officer of the Company, effective March 11, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Mardi C. Dier was appointed as Senior Vice President and Chief Financial Officer at MADRIGAL PHARMACEUTICALS, INC..

Action: appointed
Role: Senior Vice President and Chief Financial Officer

Exact text from the filing

On February 28, 2024, Madrigal Pharmaceuticals, Inc. (the “Company”) announced the appointment of Mardi C. Dier as Senior Vice President and Chief Financial Officer of the Company, effective March 11, 2024.

View on SEC.gov

MADRIGAL PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001193125-24-049136

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.